Navigation Links
Gene variant ID could lead to better fatty liver disease diagnosis
Date:4/23/2013

More patients could be diagnosed earlier with non-alcoholic fatty liver disease (NAFLD) after a cohort study presented at the International Liver CongressTM 2013 identified variants within four genes significantly associated with the histological features of the disease.

NAFLD is caused by a fatty liver; when fat is deposited in the liver not due to the use of alcohol. The spectrum of the disease is broad, ranging from simple fat deposition without inflammation (steatosis), to liver inflammation (steatohepatitis), eventually accompanied by a variable degree of fibrosis. In case of severe fibrosis progession, cirrhosis may develop. NAFLD is currently regarded as a major cause of cirrhosis of the liver of unknown cause.

As NAFLD patients are typically asymptomatic, even in the presence of more severe liver lesions, patient diagnostic techniques to identify at-risk individuals would be very helpful to improve the management of the disease.

Previous genome-wide association studies (GWAS) have provided important insights into modifier genes which influence the pathology of steatosis. Using data drawn from a large GWAS of 1125, European and North American Caucasian patients with NAFLD, this study applied a candidate-gene approach to re-examine the broader validity of these associations.

Variants within four genes significantly associated with the histological features of NAFLD were identified including steatosis (PNPLA3 rs738409, GCKR rs780094, PPP1R3B rs11777327, TRIB1 rs2385114); steatohepatitis (PNPLA3, GCKR, TRIB1); and fibrosis (PNPLA3, GCKR, TRIB1).

This study has further established the overwhelming significance of the chromosome 22 PNPLA3 locus to all aspects of NAFLD and has, for the first time, demonstrated that some genetic variations previously associated with steatosis or mild biochemical abnormalities may in fact have broader pathological significance influencing inflammatory disease and progression to fibrosis in NAFLD. A screening of these genes could be used in future genetic diagnostics to identify patient prone to development of NAFLD, if these results will be confirmed in prospective studies.


'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-079-001-68904
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. Common gene variants explain 42 percent of antidepressant response
2. An international study identifies new DNA variants that increase the risk for cancer
3. eVariant Welcomes Advocate Health Care
4. Gene variants found to affect human lifespan
5. Researchers Link 25 New Gene Variants to Autism
6. Carriers of gene variant appear less likely to develop heart disease
7. More Gene Variants Linked to Heart Trouble
8. Bigger human genome pool uncovers rarer variants
9. New gene variants raise risk of neuroblastoma, influence tumor progression
10. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
11. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: